Frontage Holdings (方达控股) IPO: Reasonable Valuation & Quality Cornerstones
Frontage Holdings, a pre-clinical CRO arm of A-share listed Hangzhou Tigermed Consulting (300347 CH), started book building today to raise up to...
969 Views
Viva Biotech (维亚生物) Post-IPO: SELL the Overvalued Incubator
Viva Biotech's IPO was priced at the top end with a very substantial oversubscription. We have highlighted in our earlier note that Viva Biotech's...
796 Views
Frontage Holdings IPO Preview: An Uncertain Transition
Frontage Laboratories Inc (1000371Z HK) is a global contract research organisation (CRO) which is backed by Hangzhou Tigermed Consulting (300347...
797 Views
ECM Weekly (4 May 2019) - Hansoh, Douyu, Eagle Hospitality, Mulsanne, Luckin
Aequitas Research puts out a weekly update on the deals that have been covered by Smartkarma Insight Providers recently, along with updates for...
1.2k Views
Viva Biotech IPO: Just About Supporting the Low-End IPO Price Range
Viva Biotech Holdings (1873 HK) is a leading global contract research organisation (CRO). It has launched its IPO to raise net proceeds of HK$1,232...
854 Views